RAF inhibitors that evade paradoxical MAPK pathway activation
暂无分享,去创建一个
James Tsai | Ying Zhang | Paul S. Lin | Wayne Spevak | Hamid Rezaei | Gaston Habets | Gideon Bollag | Prabha N. Ibrahim | Brian L. West | Marika Nespi | Jason Walters | Ben Powell | G. Habets | P. Hirth | K. Nolop | Ben J. Powell | G. Tsang | G. Bollag | J. Tsai | Weiru Wang | P. Ibrahim | Jiazhong Zhang | Chao Zhang | D. Fong | Hanna Cho | W. Spevak | Ying Zhang | Elizabeth A. Burton | B. West | Rafe Shellooe | A. Marimuthu | Hoa T. Nguyen | P. Lin | T. Ewing | Weiru Wang | Adhirai Marimuthu | Hoa Nguyen | Patrick Womack | Keith Nolop | Chao Zhang | Yan Ma | Jiazhong Zhang | Jack Lin | Todd Ewing | Bernice Matusow | Garson Tsang | Hanna Cho | Guoxian Wu | Daniel Fong | Songyuan Shi | Rafe Shellooe | Heidi Carias | Emily Light | Laura Sanftner | Gary Visor | Peter Hirth | G. Visor | Bernice Matusow | Heidi Carias | Guoxiang Wu | Marika Nespi | E. Light | J. Walters | Yanwen Ma | P. Womack | L. Sanftner | S. Shi | Hamid Rezaei | Jacki Lin | Garson Tsang
[1] N. Carragher,et al. Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma , 2015, Cancer cell.
[2] D. Morrison,et al. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. , 2013, Molecular cell.
[3] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[4] Susan S. Taylor,et al. Protein kinases: evolution of dynamic regulatory proteins. , 2011, Trends in biochemical sciences.
[5] G. Pupo,et al. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact , 2014, Clinical Cancer Research.
[6] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[7] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[8] R. Bjornson,et al. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors , 2013, Pigment cell & melanoma research.
[9] J. Wolchok,et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. , 2012, The New England journal of medicine.
[10] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[11] Sourav Bandyopadhyay,et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.
[12] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[13] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[14] A. King,et al. Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions , 2013, PloS one.
[15] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[16] D. Schadendorf,et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Alexei Vagin,et al. Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.
[18] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[19] H R Powell,et al. The Rossmann Fourier autoindexing algorithm in MOSFLM. , 1999, Acta crystallographica. Section D, Biological crystallography.
[20] Allan Balmain,et al. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas , 1984, Nature.
[21] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[22] Kaitlyn Le,et al. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells , 2013, Pigment cell & melanoma research.
[23] J. Mariadason,et al. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[25] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[26] A. Resnick,et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.
[27] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[28] A. Hauschild,et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[30] J. Wennerberg,et al. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines , 2012, Journal of Cancer Research and Clinical Oncology.
[31] R. Scolyer,et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma , 2012, The British journal of dermatology.
[32] B. Taylor,et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.
[33] K. Flaherty,et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. , 2012, The New England journal of medicine.
[34] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[35] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[36] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.